ClearB Therapeutics Announces Acceptance of Abstract Highlighting New Pre-Clinical Hepatitis B Data as a Poster Presentation at EASL 2021

CONCORD, Mass. & MELBOURNE, Australia–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract entitled �A novel therapeutic vaccine achieves functional cure in a mouse model of chronic hepatitis B’ was accepted for poster presentation at the European Association for the Study of the Liver (EASL) Digital International Liver Congress (ILC), taking place virtually June 23-26, 2021. The poster was also selected for inclusion in the ‘Best of ILC’ summary, which highlights the most noteworthy scientific contributions at this year’s meeting.

“We are excited to share our preclinical data with the Hepatitis B medical community as we move our therapeutic vaccine candidate toward the clinic,” said Aileen Rubio, PhD., Head of Research and Development for the company. ClearB Therapeutics Co-Founder and Clinical Advisory Board Chair Professor Stephen Locarnini, MBBS, PhD added, “Chronic Hepatitis B (CHB) infection is a significant world-wide disease burden that is likely to require use of combination therapies to achieve meaningful, sustained viral suppression. We believe that re-education of patients’ immune systems to break tolerance of their chronic HBV infections through co-administration of ClearB’s therapeutic vaccine could become an important component of such treatment regimens.”

Abstract Number: 853

Abstract Title: A novel therapeutic vaccine achieves functional cure in a mouse model of chronic hepatitis B 

Date: Wednesday, June 23, 2021 

Time: 8:00 AM CET (2:00 AM ET) 

Presenter Name: Dr. Renae Walsh, Senior Research Director, ClearB Therapeutics

For more information regarding EASL 2021 please visit https://easl.eu/event/the-international-liver-congress-2021/

About ClearB Therapeutics

ClearB Therapeutics was co-founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop therapeutic vaccines designed to drive functional cure of hepatitis B. The work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic hepatitis B. For more information, please visit https://clearbtherapeutics.com/.

Contacts

Wendy Gabel

Kendall Investor Relations

wgabel@kendallir.com